Literature DB >> 33190947

Understanding the perceptions of Chinese women of the commercially available domestic and imported HPV vaccine: A semantic network analysis.

Qi Wang1, Wen Zhang2, Hongning Cai3, Yuan Cao4.   

Abstract

BACKGROUND: A domestic human papillomavirus (HPV) vaccine, Cecolin, that protects against HPV strains 16 and 18 was introduced to the Chinese market at a relatively low price in May 2020.This study has explored Chinese women's perceptions of both domestic and imported HPV vaccines, which differ in price and valency.
METHODS: Sentiment analysis and semantic network analyses were performed based on a sample of 45,729 domestic HPV vaccine-related posts from females on the Sina Weibo between April 17 and May 2, 2020. The geographic distribution was also analyzed based on the users' locations, which were retrieved from the database.
RESULTS: Most of the posts were positive and neutral (85%), although 15% were negative (e.g., expressions of anger, sadness, fear and disgust). Semantic analyses of the negative posts revealed that Chinese women generally had positive attitudes towards the HPV vaccine and were willing to be vaccinated. However, obvious geographical variations were identified. Women who lived in economically developed areas expressed a stronger desire to obtain imported quadrivalent or nonavalent vaccines due to concerns regarding effectiveness and quality. The women expressed disgust and anger mainly regarding difficulties in making an appointment, age restrictions for the nonavalent vaccine and gender restrictions. However, the population targeted by the domestic vaccine, namely women who lived in economically undeveloped areas and had relatively low incomes, had a low awareness of the HPV vaccine.
CONCLUSION: Government should provide programs, which educate females that bivalent HPV vaccine can offer protection against the majority of high-risk HPV types. Increasing awareness of the domestic vaccine among the population in economically undeveloped areas and provision of free domestic bivalent HPV vaccination/screening for low-income high-risk women would help to prevent cervical carcinoma. This issue also depends on rebuilding trust and repairing damage to the relationship between government/domestic vaccine manufacturers and the public.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  China; Domestic vaccine; HPV vaccination; Semantic network analysis; Sentiment analysis

Mesh:

Substances:

Year:  2020        PMID: 33190947     DOI: 10.1016/j.vaccine.2020.11.016

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

1.  Portrayals of 2v, 4v and 9vHPV vaccines on Chinese social media: a content analysis of hot posts on Sina Weibo.

Authors:  Fangzhou Zhou; Wen Zhang; Hongning Cai; Yuan Cao
Journal:  Hum Vaccin Immunother       Date:  2021-09-20       Impact factor: 4.526

2.  Willingness to Accept Human Papillomavirus Vaccination and its Influencing Factors Using Information-Motivation-Behavior Skills Model: A Cross-Sectional Study of Female College Freshmen in Mainland China.

Authors:  Mingyu Si; Yu Jiang; Xiaoyou Su; Wenjun Wang; Xi Zhang; Xiaofen Gu; Li Ma; Jing Li; Shaokai Zhang; Zefang Ren; Yuanli Liu; Youlin Qiao
Journal:  Cancer Control       Date:  2021 Jan-Dec       Impact factor: 3.302

3.  The Lifetime Cost Estimation of Human Papillomavirus-related Diseases in China: A Modeling Study.

Authors:  Wenpei Ding; Yue Ma; Chao Ma; Daniel C Malone; Aixia Ma; Wenxi Tang; Lei Si
Journal:  J Transl Int Med       Date:  2021-09-28

4.  Investigating Media Coverage and Public Perceptions of the HPV Vaccine in China - A Content Analysis of Weibo Posts.

Authors:  Junyi Hu; Thomas William Whyke; Joaquin Lopez-Mugica
Journal:  Sex Cult       Date:  2022-09-05

5.  Social Media Mining of Long-COVID Self-Medication Reported by Reddit Users: Feasibility Study to Support Drug Repurposing.

Authors:  Jonathan Koss; Sabine Bohnet-Joschko
Journal:  JMIR Form Res       Date:  2022-10-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.